Reports
Global Sjogren’s Syndrome Treatment Market Share, Trends, Growth, Forecast: By Drug Class: Cholinergic Agonists, Off-Label Drugs; By Indication Type: Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome; By Therapeutic Agents; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Sjogren’s Syndrome Treatment Market Outlook
The Sjogren’s syndrome treatment market size was estimated to be worth USD 311.7 million. The market is expected to rise at a growth rate of 4.0% in the forecast period of 2023-2031, and by 2031, the market value is anticipated to be worth USD 427.3 million. The growing number of Sjogren’s syndrome cases and increasing awareness are the primary market drivers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Sjogren’s Syndrome Insights: Etiology, Clinical Manifestations, and Treatment
Sjogren syndrome is a chronic autoimmune disorder. This syndrome mainly affects the mouth and eye glands by reducing the amount of moisture produced by them. Depending on the development and origin, Sjogren’s syndrome is of two types- primary and secondary.
The exact cause of Sjogren’s syndrome is still unclear, but it is mainly assumed to be an autoimmune disorder. The other anticipated causes of Sjogren’s syndrome include genetic and environmental factors, sex hormones, and other viral infections.
The common signs and symptoms include dry eyes, dry mouth, muscle pain, joint pain, blurred vision, vaginal dryness, dry skin, tooth decay, dry cough, and sensation in the eyes.
Sjogren’s syndrome is diagnosed through various diagnostic tools and procedures, including blood tests, biopsy, eye exams, and imaging tests.
There is no approved treatment for the eradication of Sjogren’s syndrome, yet different therapeutic interventions have been proven beneficial for managing the symptoms. Eye drops, artificial tear solutions and autologous serum drops are generally used for treating ocular symptoms. Saliva producers and oral prescription medications are incorporated for the management of dry mouth. Depending on the symptoms, there is a change in the treatment regimen accordingly.
According to the Sjogren’s syndrome treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drug Class
- Cholinergic Agonists
- Salagen (Pilocarpine Hydrochloride)
- Evoxac (Cevimeline Hydrochloride)
- Off-Label Drugs
- Tear and Saliva Substitutes
- Cyclosporine Ophthalmic Emulsions – Restasis, Ikervis, Papilock Mini
- Topical Ophthalmic Corticosteroids – Prednisolone, Fluorometholone, Loteprednol
- Antimalarial Agents – Hydroxychloroquine
- Other Systemic Immunosuppressive Therapies – Methotrexate, Azathioprine, Cyclophosphamide
- Systemic Corticosteroids – Prednisolone, Methylprednisolone
- Biologic Agents – Rituxan (Rituximab)
Market Breakup by Indication Type
- Primary Sjogren's Syndrome
- Secondary Sjogren's Syndrome
Market Breakup by Therapeutic Agents
- Targeted Drugs
- Pain Relievers
- Symptom Modulators
- Vaccines
- Others
Sjogren’s Syndrome Treatment Market Breakup by Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Others
Market Breakup by Distribution Channel
- Retail Pharmacies
- Hospital Based Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Scenario
The growth of the Sjogren’s syndrome treatment market is driven by the rising number of Sjogren’s syndrome cases. The rise in the cases of the associated diseases that cause Sjogren’s syndrome can also be attributed to the growth of this treatment market. With the growing geriatric population, the risk and severity of the disease also increases.
Increasing research and developmental activities and flexible government initiatives are also contributing to the market growth. The rising awareness and better understanding of the entire scenario are also facilitating the market development.
Most of the therapeutic interventions are in clinical trials and can be incorporated as innovative treatments in disease management once approved. With time, novel companies are entering into mergers and acquisitions with other companies to expand their product portfolio. This will increase sales and profits and propel market growth and development.
Regional Outlook
North America is expected to dominate the market owing to its higher prevalence rate and advanced healthcare infrastructure facilities.
The Asia Pacific region is anticipated to be the fastest-growing region due to the rising geriatric population, developing healthcare infrastructure, and increasing economies. The flexible government policies and rising government spending in the healthcare sector are also contributing to Sjogren’s syndrome treatment market growth in this region.
Therapeutic Landscape
The exact diagnosis of Sjogren’s syndrome is a bit difficult and often leads to several complications. The treatment for this syndrome depends on the affected part of the body. The initial symptoms, such as dry eyes or dry mouth, are managed by using over-the-counter eye drops at regular intervals. For the management of serious conditions, prescription medications and surgical procedures are considered suitable treatment options.
Sjogren’s Syndrome Therapeutic Prospects
Prescription eyedrops like Cyclosporin and Lifitegrast are considered the first-line treatment for the alleviation of eye inflammation and other ocular symptoms. Other common symptoms like dry mouth are treated using the drugs pilocarpine and cevimeline which facilitate saliva production in the mouth. General drugs, such as Methotrexate and Hydroxychloroquine are used to treat the systemwide symptoms.
A surgical procedure is the last treatment option in severe cases. It is a minimally invasive procedure to seal the tear ducts that are responsible for tear drainage in the eyes. Collagen or silicone plugs are placed into the ducts to stop the tear drainage.
Several homecare remedies such as the application of artificial tears gels and ointments help in the alleviation of the symptoms. Preventative measures, such as increasing fluid intake and maintaining oral hygiene, are also helpful in the syndrome prevention.
Clinical Trials Landscape
Several clinical trials for Sjogren’s syndrome are being developed and researched by healthcare organisations and pharma companies. To get a safer and more efficient treatment for Sjogren’s syndrome, investigators continuously search, analyse, and reformulate current therapies and treatments. They are more drawn toward the study of the new treatment with new targeted therapies.
Emerging Drugs Expected to Aid the Sjogren’s Syndrome Treatment Market Growth
Current management techniques are mainly empirical and provide only symptomatic relief for patients. The clinical studies are primarily focused on novel methods to treat B cells and co-stimulation targets.
Horizon therapeutics, a key market player, is evaluating dazodalibep under Phase II clinical trials for treating modern to high systemic disease activity. This drug is designed to block the interaction between CD-40 and its receptor, thus managing its autoimmune activity.
Ianalumab, an exploratory drug has also shown potential effects under Phase II clinical trials. The drug has exhibited improved results in the Sjogren’s syndrome disease activity index score and health-related quality of life.
Telicacept, another experimental drug, is being discovered by RemeGen for treating the primary Sjogren’s syndrome. This drug is in Phase II trials and contains two parts, an antibody called immunoglobin G and part of a protein known as TACI. Several ongoing clinical trials are also propelling the growth of the market growth.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the Sjogren’s syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Denali Therapeutics
- Clovis Oncology
- Horizon Therapeutics plc
- Sangamo Therapeutics
- AbbVie Inc.
- Advanz Pharma
- Biogen Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Hikma Pharmaceuticals plc
- Johnson and Johnson
- Sanofi S.A.
- Sun Pharmaceutical Industries Limited
- Novartis AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Indication Type |
|
| Breakup by Therapeutic Agents |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Sjogren’s Syndrome Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Sjogren’s Syndrome Treatment Market
8.1 Global Sjogren’s Syndrome Treatment Market Overview
8.2 Global Sjogren’s Syndrome Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Sjogren’s Syndrome Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Sjogren’s Syndrome Treatment Market Forecast Value (2023-2031)
8.3 Global Sjogren’s Syndrome Treatment Market by Drug Class
8.3.1 Market Overview
8.3.1.1 Cholinergic Agonists
8.3.1.1.1 Salagen (Pilocarpine Hydrochloride)
8.3.1.1.2 Evoxac (Cevimeline Hydrochloride)
8.3.1.2 Off-Label Drugs
8.3.1.2.1 Tear and Saliva Substitutes
8.3.1.2.2 Cyclosporine Ophthalmic Emulsions – Restasis, Ikervis, Papilock Mini
8.3.1.2.3 Topical Ophthalmic Corticosteroids – Prednisolone, Fluorometholone, Loteprednol
8.3.1.2.4 Antimalarial Agents – Hydroxychloroquine
8.3.1.2.5 Other Systemic Immunosuppressive Therapies – Methotrexate, Azathioprine, Cyclophosphamide
8.3.1.2.6 Systemic Corticosteroids – Prednisolone, Methylprednisolone
8.3.1.2.7 Biologic Agents – Rituxan (Rituximab)
8.4 Global Sjogren’s Syndrome Treatment Market by Indication Type
8.4.1 Market Overview
8.4.1.1 Primary Sjogren's Syndrome
8.4.1.2 Secondary Sjogren's Syndrome
8.5 Global Sjogren’s Syndrome Treatment Market by Therapeutic Agents
8.5.1 Market Overview
8.5.1.1 Targeted Drugs
8.5.1.2 Pain Relievers
8.5.1.3 Symptom Modulators
8.5.1.4 Vaccines
8.5.1.5 Others
8.6 Global Sjogren’s Syndrome Treatment Market by Route of Administration
8.6.1 Market Overview
8.6.1.1 Oral
8.6.1.2 Intravenous
8.6.1.3 Subcutaneous
8.6.1.4 Others
8.7 Global Sjogren’s Syndrome Treatment Market by Distribution Channel
8.7.1 Market Overview
8.7.1.1 Retail Pharmacies
8.7.1.2 Hospital Based Pharmacies
8.7.1.3 Online Pharmacies
8.8 Global Sjogren’s Syndrome Treatment Market by Region
8.8.1 Market Overview
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 North America Sjogren’s Syndrome Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Sjogren’s Syndrome Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Sjogren’s Syndrome Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Sjogren’s Syndrome Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Sjogren’s Syndrome Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Sjogren’s Syndrome Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Denali Therapeutics
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Clovis Oncology
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Horizon Therapeutics plc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Sangamo Therapeutics
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 AbbVie Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Advanz Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Biogen Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Bristol-Myers Squibb Company
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Daiichi Sankyo Company, Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Hikma Pharmaceuticals plc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Johnson and Johnson
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Sanofi S.A.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Sun Pharmaceutical Industries Limited
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Novartis AG
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Global Sjogren’s Syndrome Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Based on the drug class, the market has been divided into cholinergic agonists and off-label drugs.
Based on the indication type, the market has been segmented into primary and secondary Sjogren’s syndrome.
Based on the treatment method, the market has been categorised into targeted drugs, pain relievers, symptom modulators, and vaccines.
What is the breakup of the Sjogren’s syndrome treatment market based on the route of administration?
Based on the route of administration, the market is segmented into oral, intravenous, and subcutaneous, among others.
Based on the distribution channels, the market is classified into retail pharmacies, hospital-based pharmacies, and online pharmacies.
The rising number of Sjogren’s syndrome cases, increasing research and development activities and growing mergers and acquisitions are driving the growth of the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in the market are Denali Therapeutics, Clovis Oncology, Horizon Therapeutics plc, Sangamo Therapeutics, AbbVie Inc., Advanz Pharma, Biogen Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Hikma Pharmaceuticals plc, Johnson and Johnson, Sanofi S.A., Sun Pharmaceutical Industries Limited, and Novartis AG, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER